sirusertib   Click here for help

GtoPdb Ligand ID: 14633

Synonyms: ACR-2316 | compound 109 [WO2024254490]
Compound class: Synthetic organic
Comment: Sirusertib is the INN for a serine/threonine kinase inhibitor, that was included in WHO INN Proposed List 135 (July 2026). The chemical structure matches one of those claimed as WEE1/PKMYT1 dual inhibitors in Acrivon Therapeutics' patent WO2024254490A1 [1]. It is likely that sirusertib is the proposed INN for Acrivon's clinical candidate ACR-2316.
Sirusertib is proposed to disrupt WEE1 and PKMYT1-regulated cell cycle checkpoints in cancer cells that are sensitised by existing defective G1/S checkpoint control, thus leading to cell death.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 11
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 100.73
Molecular weight 511.58
XLogP 0.42
No. Lipinski's rules broken 2

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C=CCN1C(=O)C2=C(N=C(N=C2)NC3=CC4=C(C=C3)N(C)N=C4)N1C5=CC=CC(=N5)OC6CCN(C)CC6
Isomeric SMILES CN1CCC(CC1)OC2=CC=CC(=N2)N3C4=NC(=NC=C4C(=O)N3CC=C)NC5=CC6=C(C=C5)N(N=C6)C
InChI InChI=1S/C27H29N9O2/c1-4-12-35-26(37)21-17-28-27(30-19-8-9-22-18(15-19)16-29-34(22)3)32-25(21)36(35)23-6-5-7-24(31-23)38-20-10-13-33(2)14-11-20/h4-9,15-17,20H,1,10-14H2,2-3H3,(H,28,30,32)
InChI Key XQDYSXUTWDXVTN-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
ACR-2316 was progressed as an oncology candidate.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06667141 Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors Phase 1 Interventional Acrivon Therapeutics